BioCentury
ARTICLE | Clinical News

Generx alferminogene: Phase IIb/III data

September 3, 2007 7:00 AM UTC

Pooled data from 2 double-blind, U.S. and international Phase IIb/III trials (AGENT-3 and AGENT-4) showed that a pre-specified subgroup of 72 women receiving the high dose of Ad5FGF4 had significant i...